Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

[1]  P. Brown,et al.  Molecularly targeted therapies for p53-mutant cancers , 2017, Cellular and Molecular Life Sciences.

[2]  C. Martyniuk,et al.  Optimal alpha reduces error rates in gene expression studies: a meta-analysis approach , 2017, BMC Bioinformatics.

[3]  F. Jardin,et al.  Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma , 2017, Oncotarget.

[4]  Ranganatha R. Somasagara,et al.  Targeting MYC Dependence by Metabolic Inhibitors in Cancer , 2017, Genes.

[5]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[6]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[7]  Rajendu Srivastava,et al.  A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs , 2016, Journal of oncology practice.

[8]  J. Pinilla-Ibarz,et al.  Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned , 2016, OncoTargets and therapy.

[9]  C. Kelly,et al.  The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. , 2016, Journal of gastrointestinal oncology.

[10]  S. Hurvitz,et al.  Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. , 2016, Clinical advances in hematology & oncology : H&O.

[11]  A. Akobeng.  Understanding type I and type II errors, statistical power and sample size , 2016, Acta paediatrica.

[12]  J. Kostic,et al.  Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses , 2016, International journal of molecular sciences.

[13]  M. Weller,et al.  Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives , 2016, Expert opinion on pharmacotherapy.

[14]  Peng Liu,et al.  Sample size calculation while controlling false discovery rate for differential expression analysis with RNA-sequencing experiments , 2016, BMC Bioinformatics.

[15]  M. Cole,et al.  Strategically targeting MYC in cancer , 2016, F1000Research.

[16]  W. Wick,et al.  Gliome: Aktuelle Entwicklungen in der Diagnostik und Therapie , 2016, Deutsches Ärzteblatt Online.

[17]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[18]  Johnny Lo,et al.  Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma , 2015, Oncotarget.

[19]  J. Kros,et al.  Contemporary frameless intracranial biopsy techniques: Might variation in safety and efficacy be expected? , 2015, Acta Neurochirurgica.

[20]  J. Ptak,et al.  Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord , 2015, Proceedings of the National Academy of Sciences.

[21]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[22]  Y. Ko,et al.  Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. , 2015, Anticancer research.

[23]  T. Wurdinger,et al.  Liquid biopsies in patients with diffuse glioma , 2015, Acta Neuropathologica.

[24]  G. Selivanova,et al.  Pharmacological reactivation of p53 as a strategy to treat cancer , 2015, Journal of internal medicine.

[25]  C. Liang,et al.  p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma , 2014, Molecular Cancer Research.

[26]  T. Shirakawa,et al.  A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. , 2014, Anticancer research.

[27]  K. Hoang-Xuan,et al.  Mutational analysis of primary central nervous system lymphoma , 2014, Oncotarget.

[28]  L. Butterfield,et al.  Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer , 2014, Clinical Cancer Research.

[29]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Siebert,et al.  Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice , 2014, Acta Neuropathologica.

[31]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[32]  D. Hoon,et al.  Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients , 2013, Expert review of molecular diagnostics.

[33]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[34]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[35]  M. Zavoral,et al.  Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. , 2013, Analytical biochemistry.

[36]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[37]  A. Ferreri,et al.  Primary CNS lymphoma. , 2012, Best practice & research. Clinical haematology.

[38]  Xiujie Wu,et al.  Prognostic Value of Free DNA Quantification in Serum and Cerebrospinal Fluid in Glioma Patients , 2012, Journal of Molecular Neuroscience.

[39]  Paul A. Rejto,et al.  An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 , 2012, Molecular Cancer Therapeutics.

[40]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[41]  T. Buchholz,et al.  MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells , 2011, Clinical Cancer Research.

[42]  Hong Lin,et al.  Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. , 2010, Neuro-oncology.

[43]  A. Banerjee,et al.  Hypothesis testing, type I and type II errors , 2009, Industrial psychiatry journal.

[44]  M. Pierotti,et al.  Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients , 2007, International journal of cancer.

[45]  S. O’Day,et al.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. , 2006, Cancer research.

[46]  J. Herman,et al.  Methylated Tumor-Specific DNA as a Plasma Biomarker in Patients with Glioma , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Lindström,et al.  Role of genetic and epigenetic changes in Burkitt lymphoma. , 2002, Seminars in cancer biology.

[49]  W. Feiden,et al.  [Primary CNS lymphomas. Morphology and diagnosis]. , 2002, Der Pathologe.

[50]  J. Crown,et al.  Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer? , 2017, International journal of cancer.

[51]  Tyler A. Davis,et al.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. , 2015, Cancer research.